It was initially thought Lp(a) would need to be measured only once, but data suggest it can fluctuate in some people.

The interconnection is far deeper than previously thought, raising new ways to promote health, says Fernando Testai.

Whether to use ATP is not clear-cut and the choice should be made through shared decision-making, one expert says.

Surviving a SARS-CoV-2 infection may be a reason to be more vigilant about general CV prevention measures moving forward.

CCCTN registry data reinforce the message that DanGer Shock’s findings supporting MCS apply narrowly to patients studied.

It’s time for an endpoint that includes quality of life and mortality, and weights events accordingly, says one surgeon.

The novel GLP-1 receptor agonists will likely reduce the need for CABG and improve surgical outcomes, several argue.

The experts provide a how-to on dealing with sticky situations, such as no-flow and large thrombus, during PCI for STEMI.

The data shed more light on how patients in the real world are faring after CAR T-cell treatment, says Sarju Ganatra.

A study reinforces the importance of supporting the arm and placing the BP cuff at heart level, as guidelines recommend.

Indications that the GLP-1 drug has greater benefits in the most frail patients should be viewed cautiously, one expert says.

The incidental mammogram finding isn’t a reason to panic, but it might a reason to make sure other risk factors are under ...